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INTRODUCTION

DISCUSSION

Gastroparesis is a disorder of the stomach involving a
delay in the emptying of gastric contents that typically
presents with nausea, vomiting, early satiety, and weight
loss. Though commonly associated with diabetes or as
a complication of surgical procedures, etiologies
stemming from paraneoplastic processes are important
to consider despite often being overlooked. The case
presented here describes a patient with a significant
malignancy history and evidence of severely impaired
gastric emptying concerning for paraneoplastic
gastroparesis and highlights the evaluation, diagnosis,
and management of the condition.

Paraneoplastic Gastroparesis, although an uncommon
cause of delayed gastric emptying, is an important
diagnosis to consider in severe cases without other
obvious etiologies. Although diabetes and surgical
complications account for greater than 42 percent of
cases of gastroparesis, paraneoplastic syndromes should
not be excluded as a possible cause of delayed gastric
empying as it can often be the presenting symptom of an
underlying malignancy1,2 . Paraneoplastic gastroparesis
has most commonly been observed in patients with lung,
pancreatic, gallbladder, uterine or other soft tissue
malignancies3 . Knowing these common associations is
an important factor to consider when evaluating a patient
with delayed gastric emptying and concurrent cancer as
it can inform ones clinical suspicion for a parneoplastic
cause. Even when commorbidities that are more
commonly associated with gastroparesis are present,
malignancy should always be considered.

CASE PRESENTATION
The patient is a 73-year-old man with a past medical
history notable for chronic lymphocytic leukemia
recently on ibrutinib, prostate cancer s/p surgical
resection, non-small cell lung cancer s/p pulmonary
lobectomy, hypothyroidism, and hepatitis C cirrhosis
who presented to the office for evaluation of poor oral
intake, inability to carry out activities of daily living, and
altered mental status. History was limited given the
patient’s poor mental status, however he did endorse
15lb weight loss and decreased appetite. He denied
any nausea, vomiting, abdominal pain, or change in
bowel habits. Physical exam was notable for an overall
frail appearing male with dry mucous membranes, and
an abdominal exam without distention, or tenderness
to palpation. Cardio-pulmonary examinations were
unremarkable. Relevant laboratory data included a
TSH of 0.48 uU/L (0.30-5.00 uIU/mL), and a hemoglobin
A1c 4.9 (NL<5.7%) obtained 5 months prior. The patient
recently received a gastric emptying study which
showed severely impaired gastric emptying with 50%
gastric retention at greater than 28.5 hours (NL <10%
retained at four hours). Computer Tomography (CT)
showed evidence of diffuse lymphadenopathy, a new
hepatic hypodensity, but no evidence of extrinsic
compression of the gastric outlet. Anti-Jo1 Ab and
Hu antibodies were sent to further evaluate for a
possible paraneoplastic etiology however he was
discharged home prior to these tests resulting given
his clinical stability.
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In patients with a significant history of maligancy as
presented here, identifying and resolving confirmed
cases of paraneoplastic gastroparesis relies on successful
identification of the underlying malignancy through
tissue diagnosis via biopsy. A less invasive method for
screening for paraneoplastic gastoparesis prior to
attempting biopsy is through serologic testing. A case
series by Lee et al. focused on the evaluation of paraneoplastic gastrointesinal motility dysfunction and noted
positive paraneoplastic antibodies in 10 of 11 cases
reviewed 4 . Despite small study populations, similar
studies support antibody screening with type 1
antineuronal nuclear antibody (ANNA-1 or anti-Hu
antibody) and cytoplasmic purkinje cell (Anti-Yo)
antibodies in patients with suspicion for paraneoplastic
gastroparesis 4,5 . Serology testing has become an
important step in the diagnosis of paraneoplastic
gastroparesis. The paraneoplastic syndrome is confirmed
with the detection of positive onco-neural antibodies or
onset of symptoms within five years of the development
of cancer6 . Baig et al. highlighted that diagnosis likely
holds prognostic value as well given that patients with
paraneoplastic gastroparesis showed symptomatic
improvement after surgical resection, chemotherapy, or
radiation treatment of underlying malignancy in 6 of 14
cases reviewed 5 . Traditional therapies for gastroparesis

such as frequent small meals, anti-emetics, and
pro-kinetic agents like metaclopromide and erythromycin
are still utilized to help alleviate symptoms.
The case presented here demonstrates the need to fully
investigate symptoms of weight loss, poor oral intake,
nausea, and vomiting in this patient population as they
could be explained by and lead to the diagnosis of a new
disease process such as paraneopastic gastroparesis. This
case highlights severely pathologic gastric emptying in a
patient with a significant history of malignancy and
emphasizes the importance of considering a paraneoplastic syndrome as a possible cause of gastroparesis.
Delayed gastric emptying, especially in patients with
underlying malignancy is an often overlooked disease
process that requires thorough evaluation with imaging
and serologic testing.
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